21 Recruiting Studies Using Decitabine And Cedazuridine
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Decitabine And Cedazuridine
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Locally Advanced Unresectable Primary Central Chondrosarcoma
View Study & Checklist ➔ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
📍 M D Anderson Cancer Center — Houston, Texas
Chronic Phase Chronic Myelogenous Leukemia
View Study & Checklist ➔Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Recurrent Acute Biphenotypic Leukemia
View Study & Checklist ➔Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
📍 USC Norris Comprehensive Cancer Center — Los Angeles, California
Acute Myeloid Leukemia
View Study & Checklist ➔Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Acute Myeloid Leukemia
View Study & Checklist ➔Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
📍 OHSU Knight Cancer Institute — Portland, Oregon
Acute Myeloid Leukemia
View Study & Checklist ➔Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Chronic Myelomonocytic Leukemia
View Study & Checklist ➔Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Chronic Myelomonocytic Leukemia
View Study & Checklist ➔Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Recurrent B-Cell Non-Hodgkin Lymphoma
View Study & Checklist ➔Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
📍 Illinois CancerCare-Bloomington — Bloomington, Illinois
Acute Myeloid Leukemia
View Study & Checklist ➔Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
📍 Banner University Medical Center - Tucson — Tucson, Arizona
Acute Myeloid Leukemia
View Study & Checklist ➔A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
📍 Children's Hospital of Alabama — Birmingham, Alabama
Acute Myeloid Leukemia Post Cytotoxic Therapy
View Study & Checklist ➔ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
📍 Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
Myelodysplastic Syndrome
View Study & Checklist ➔A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
📍 UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
Accelerated Phase Myeloproliferative Neoplasm
View Study & Checklist ➔MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Acute Myeloid Leukemia
View Study & Checklist ➔Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
📍 Yale University — New Haven, Connecticut
Acute Myeloid Leukemia
View Study & Checklist ➔Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Accelerated Phase Myeloproliferative Neoplasm
View Study & Checklist ➔Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔